tldrdailynews.com logo
Tag

Drug Pricing

All articles tagged with #drug pricing

Two Decades of GLP-1s: Obesity, Economy, and Culture in the Ozempic Era
health5 days ago

Two Decades of GLP-1s: Obesity, Economy, and Culture in the Ozempic Era

A BuzzFeed News piece gathers Reddit discussions and user anecdotes to explore how GLP-1 medications (like Ozempic, Wegovy, and Mounjaro) could reshape society over 20 years. Predictions span obesity becoming a “disease of poverty,” shifts in beauty standards toward muscle or other traits, and the role of patent expirations and pricing in global access. The article also highlights potential economic and geopolitical effects, factory shifts in the food and insurance industries, and debates over long‑term health impacts and craving dynamics, all illustrating a future where widespread GLP-1 use could alter health, wealth, and culture.

via BuzzFeed|
#drug-pricing#glp-1-drugs#health
Trump drug-price rule targets 340B markups, forecasting $1.1B in Medicare savings
politics8 days ago

Trump drug-price rule targets 340B markups, forecasting $1.1B in Medicare savings

AP live updates report the Trump administration proposing a rule to bar hospitals from charging markups on discounted drugs for Medicare patients under the 340B program, potentially saving $1.1 billion next year; the feed also covers former CIA Director John Brennan's lawsuit to preserve records, Trump's maiden flight on a retrofitted Air Force One, his visit to the Theodore Roosevelt Presidential Library, and plans for Trump's Accounts that would give newborns $1,000.

via AP News|
#340b#brennan#drug-pricing
TrumpRx.gov Expansion Opens Transparent, Discounted Generics for Americans
healthcare1 month ago

TrumpRx.gov Expansion Opens Transparent, Discounted Generics for Americans

President Trump announced an expansion of TrumpRx.gov to list more than 600 generic medications with transparent cash prices, enabling patients to compare the best cash prices at local pharmacies or delivery options against insurance co-pays, and integrating discounts from Amazon Pharmacy, Cost Plus Drugs, and GoodRx; the platform excludes controlled substances and meds not commonly offered direct-to-consumer, building on prior executive actions to lower US drug costs.

via The White House (.gov)|
#drug-pricing#generic-meds#healthcare
Trump unveils Regeneron pact to lower Medicaid drug costs
politics2 months ago

Trump unveils Regeneron pact to lower Medicaid drug costs

President Trump announced a deal with Regeneron to reduce prices on all Regeneron drugs sold on Medicaid, including Praluent at $225 on the TrumpRx site, as part of a broader White House drug-pricing push. Regeneron also pledged about $27 billion in U.S. R&D/manufacturing investments. Details of the contracts remain largely undisclosed, but the administration is promoting the agreements ahead of the midterm elections as part of its effort to reshape U.S. drug pricing.

via PBS|
#drug-pricing#medicaid#politics
Regeneron trims prices for some Americans and pledges free hearing-loss gene therapy after FDA nod
business2 months ago

Regeneron trims prices for some Americans and pledges free hearing-loss gene therapy after FDA nod

Regeneron said it will lower U.S. drug prices for some Americans under President Trump’s pricing plan and will offer its first hearing-loss gene therapy for free to eligible patients after regulatory approval, while also securing a three-year tariff exemption; the therapy Otarmeni targets a rare hearing-loss condition and could reduce reliance on cochlear implants, with analysts signaling potential peak sales around $130 million.

via CNBC|
#business#drug-pricing#gene-therapy
politics2 months ago

Capitol Hill in Overdrive: Fed Oversight, Redistricting, and Immigration Dominate the Week

Capitol Hill is in overdrive as lawmakers tackle a torrent of issues: Senate Republicans push for increased Federal Reserve oversight to help clear the stalled Warsh nomination, while a GOP-leaning standoff over a DOJ probe adds friction. Across the Hill, Rep. Kean Jr.’s health-related absence raises concerns in New Jersey, a marathon “vote-a-rama” on immigration-enforcement funding looms in the Senate, and debate over Iran war powers intensifies as a 60-day clock nears. The Senate also moves to expand AI tools for staff, questions Kennedy’s vaccine policy, and Sanders pushes a drug-pricing amendment. In the House, FISA extension talks continue as the Endangered Species Act bill is pulled, and Virginia Democrats celebrate a redistricting win that has Hakeem Jeffries declaring “maximum warfare” in response. Polls show historic disapproval of Congress amid these fights, alongside ongoing discussions about data privacy and other Republican pregnancies on the Hill.

via Politico|
#congressional-oversight#drug-pricing#federal-reserve
politics2 months ago

House GOP weighs narrow immigration bill against broader reform amid FISA and redistricting drama

Live Capitol Hill updates show House Republicans weighing a quick, party-line reconciliation bill funding immigration enforcement, with support hinging on prospects for a broader package later in the year; leadership struggles over extending 702 FISA and potential long-term protections; the Endangered Species Act bill is pulled amid GOP opposition; discussions about a possible DOJ pardon for Ghislaine Maxwell surface in the Epstein case; Sanders moves to codify Trump's drug-price deals in the budget vote-a-rama; Virginia's mid-decade redistricting sparks intra-party tension as Democrats celebrate map changes; and Congress grapples with historically low public approval while Democrats prepare a marathon of affordability-focused amendments.

via Politico|
#drug-pricing#fisa#maxwell-pardon
Kennedy’s Capitol Hill comeback faces diminished clout amid vaccine-policy scrutiny
politics2 months ago

Kennedy’s Capitol Hill comeback faces diminished clout amid vaccine-policy scrutiny

Health Secretary Robert F. Kennedy Jr. returns to Capitol Hill with diminished autonomy, facing a gauntlet of vaccine-related questions from House Ways and Means, Appropriations, and Senate committees as his administration’s changes—and court setbacks—have undercut his influence; critics cite the January overhaul of the childhood vaccine schedule and CDC updates tied to his stance, while supporters point to drug-pricing deals and new dietary guidelines as he maneuvers a shifting political landscape ahead of the midterms.

via Axios|
#congress#drug-pricing#politics
Keytruda's fortress: Merck's patent-and-pricing empire under global scrutiny
business2 months ago

Keytruda's fortress: Merck's patent-and-pricing empire under global scrutiny

An ICIJ investigation shows Merck’s Keytruda has become one of the world’s best-selling drugs not just because of therapeutic value but due to an expansive patent portfolio (more than 1,200 filings in 53 countries), lobbying, and pricing tactics that raise costs for patients worldwide while governments and insurers struggle to fund access; the report details price disparities, secrecy, accelerated approvals, and strategic moves like drug-dosing and product hopping that help Merck extend monopoly into the 2030s, with patients in India, Guatemala, the U.S. and elsewhere paying vast out-of-pocket or facing restricted access.

via International Consortium of Investigative Journalists - ICIJ|
#access-to-medicine#business#drug-pricing
politics3 months ago

PhRMA's Steve Ubl to step down by year-end, triggering CEO search

Steve Ubl, CEO of the Pharmaceutical Research and Manufacturers of America, will depart at the end of the year after a decade leading the branded-drug lobby, leaving a leadership gap as Congress pressures lower drug costs and the administration pursues pricing reforms. The board will search for a successor, with Ubl remaining through a smooth transition; Lori Reilly is considered a leading internal candidate as PhRMA navigates IRA-era price negotiations and rising industry scrutiny.

via Politico|
#drug-pricing#lobbying#lori-reilly
TrumpRx: Small Discounts, Big Questions on Real Price Relief
health3 months ago

TrumpRx: Small Discounts, Big Questions on Real Price Relief

TrumpRx.gov, launched to curb prescription costs, has offered discounts on only 54 drugs—many with cheaper generics or other savings options—and remains far from an insurance-friendly tool, with limited awareness; experts say its real impact hinges on scale, broader drug coverage, price transparency, and potential congressional action to codify MFN-style deals into law.

via NBC News|
#drug-pricing#health#health-policy
TrumpRx Promises Grand Savings, Delivers Narrow Drug List After One Month
healthcare4 months ago

TrumpRx Promises Grand Savings, Delivers Narrow Drug List After One Month

One month after its launch, TrumpRx has only a small catalog of drugs (44 listed) despite lofty promises of broad discounts, with many items already available as generics and no clear usage data released. Private deals with drugmakers remain in flux, limiting impact on prices, while administration officials trumpet progress amid bipartisan scrutiny and questions about affordability gains for most patients.

via statnews.com|
#drug-pricing#generics#healthcare
TrumpRx Debuts Amid Skepticism Over Pricing Impact
politics5 months ago

TrumpRx Debuts Amid Skepticism Over Pricing Impact

The White House launched TrumpRx (trumprx.gov) to help uninsured Americans find discounted prices for high-cost, brand-name drugs. It doesn’t sell drugs directly; users browse discounted medicines and either receive coupons at pharmacies or are redirected to manufacturers’ sites. Discounts come from voluntary 'most favored nation' deals with 16 major drugmakers, but full terms are not public. Economists say the savings are likely modest and mainly increase price transparency; the platform could help those not covered by insurance, especially for lifestyle drugs like fertility or weight-loss treatments. Democrats criticize it as a vanity project and raise concerns about potential conflicts with BlinkRx and Trump family involvement; long-term impact remains uncertain.

via latimes.com|
#blinkrx#democrats#drug-pricing